Sanofi

CAC 40Health careSANFR0000120578

A. is a French multinational pharmaceutical and healthcare company headquartered in Paris.

Filings

267 filings

All Inside information267 Share buyback113 Voting rights and capital36 Earnings release9 Half-year financial report2 Universal registration document2 Threshold crossing1 Annual financial report1

05/03/2025
Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires
Inside informationFrench
25/02/2025
Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Inside information
22/02/2025
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
Inside informationFR
19/02/2025
Press Release: Sanofi and CD&R sign Opella share purchase agreement
Inside informationFR
18/02/2025
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Inside informationFR
13/02/2025
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Inside informationFR
13/02/2025
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Inside informationFR
07/02/2025
Press Release: Execution of a share buyback agreement for up to €2 billion
Inside informationFR
03/02/2025
Press Release: Sanofi announces buy back of shares from L’Oréal
Inside informationFR
31/01/2025
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Inside informationFR
30/01/2025
Communiqué de presse : Croissance des ventes de 10,3% au T4. Objectif du BNPA des activités de 2024 dépassé. Fort rebond du BNPA des activités attendu en 2025
Inside informationFrench
22/01/2025
Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
Inside informationFR
21/01/2025
Press Release: Opella reaches study milestone for Cialis
Inside informationFR
13/01/2025
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Inside informationFR
09/01/2025
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
Inside informationFR

About

ISIN: FR0000120578
Ticker: SAN
LEI: 549300E9PC51EN656011
Sector: Health care
Founded: 2004
Employees: 106,566
Country of registration: FR
Last filing: 04/08/2026, 07:00

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive